Altimmune’s Strategic Moves Spark M&A Buzz: Is It The Hottest Player In Obesity & Liver Disease?

Altimmune presented its fourth quarter and full-year 2024 financial results, focusing on significant milestones and upcoming developments. The company has made strides in its clinical programs, especially its lead candidate, pemvidutide, intended for the treatment of non-alcoholic steatohepatitis (NASH), alongside addressing obesity and other potential indications. On the clinical front, Altimmune has advanced its IMPACT trial, a Phase IIb study of pemvidutide in NASH, which aims to demonstrate NASH resolution and fibrosis improvement after a 24-week treatment period. A successful outcome would differentiate pemvidutide as the first incretin-based agent to show significant fibrosis improvement within this timeframe. The company plans to engage with the FDA for an end-of-Phase II meeting based on these outcomes, aiming to align on initiating a Phase III program in NASH by early 2026.